353 related articles for article (PubMed ID: 21502972)
1. Limitations of angiotensin inhibition.
Nobakht N; Kamgar M; Rastogi A; Schrier RW
Nat Rev Nephrol; 2011 Jun; 7(6):356-9. PubMed ID: 21502972
[TBL] [Abstract][Full Text] [Related]
2. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Ruggenenti P; Cravedi P; Remuzzi G
Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
Yamout H; Lazich I; Bakris GL
Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
[TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
Atlas SA
J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):9-20. PubMed ID: 17970613
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
9. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
10. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
11. [The renin-angiotensin-aldosterone system -- more complex as previously thought].
Wolf G
Med Klin (Munich); 2005 Aug; 100(8):471-7. PubMed ID: 16096728
[TBL] [Abstract][Full Text] [Related]
12. Targeting the renin angiotensin system for remission/regression of chronic kidney disease.
Macconi D
Histol Histopathol; 2010 May; 25(5):655-68. PubMed ID: 20238303
[TBL] [Abstract][Full Text] [Related]
13. Direct renin inhibition and the kidney.
Hollenberg NK
Nat Rev Nephrol; 2010 Jan; 6(1):49-55. PubMed ID: 19935744
[TBL] [Abstract][Full Text] [Related]
14. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
16. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
17. Update on role of direct renin inhibitor in diabetic kidney disease.
Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
[TBL] [Abstract][Full Text] [Related]
18. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor blockers: RAAS blockade and renoprotection.
Ruilope LM
Curr Med Res Opin; 2008 May; 24(5):1285-93. PubMed ID: 18366863
[TBL] [Abstract][Full Text] [Related]
20. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
Dalla Vestra M; Simioni N; Masiero A
Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
